Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ZNF106_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ZNF106_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ZNF106_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ZNF106_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ZNF106_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ZNF106_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ZNF106_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ZNF106_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:1901653 | Colorectum | AD | cellular response to peptide | 114/3918 | 359/18723 | 8.32e-07 | 2.88e-05 | 114 |
GO:0032869 | Colorectum | AD | cellular response to insulin stimulus | 72/3918 | 203/18723 | 1.10e-06 | 3.68e-05 | 72 |
GO:0071375 | Colorectum | AD | cellular response to peptide hormone stimulus | 95/3918 | 290/18723 | 1.50e-06 | 4.66e-05 | 95 |
GO:0043434 | Colorectum | AD | response to peptide hormone | 126/3918 | 414/18723 | 2.70e-06 | 7.86e-05 | 126 |
GO:00434343 | Colorectum | FAP | response to peptide hormone | 100/2622 | 414/18723 | 1.74e-08 | 1.84e-06 | 100 |
GO:19016533 | Colorectum | FAP | cellular response to peptide | 89/2622 | 359/18723 | 2.93e-08 | 2.64e-06 | 89 |
GO:00713753 | Colorectum | FAP | cellular response to peptide hormone stimulus | 75/2622 | 290/18723 | 5.60e-08 | 4.29e-06 | 75 |
GO:00328683 | Colorectum | FAP | response to insulin | 68/2622 | 264/18723 | 2.71e-07 | 1.55e-05 | 68 |
GO:00328693 | Colorectum | FAP | cellular response to insulin stimulus | 54/2622 | 203/18723 | 1.54e-06 | 6.59e-05 | 54 |
GO:0008286 | Colorectum | FAP | insulin receptor signaling pathway | 28/2622 | 116/18723 | 2.37e-03 | 1.89e-02 | 28 |
GO:00434344 | Colorectum | CRC | response to peptide hormone | 76/2078 | 414/18723 | 6.67e-06 | 2.56e-04 | 76 |
GO:00328684 | Colorectum | CRC | response to insulin | 53/2078 | 264/18723 | 1.30e-05 | 4.17e-04 | 53 |
GO:00328694 | Colorectum | CRC | cellular response to insulin stimulus | 42/2078 | 203/18723 | 4.79e-05 | 1.12e-03 | 42 |
GO:00713754 | Colorectum | CRC | cellular response to peptide hormone stimulus | 55/2078 | 290/18723 | 4.82e-05 | 1.12e-03 | 55 |
GO:19016534 | Colorectum | CRC | cellular response to peptide | 64/2078 | 359/18723 | 8.54e-05 | 1.75e-03 | 64 |
GO:00082861 | Colorectum | CRC | insulin receptor signaling pathway | 23/2078 | 116/18723 | 4.02e-03 | 3.33e-02 | 23 |
GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF106 | SNV | Missense_Mutation | | c.1133C>T | p.Pro378Leu | p.P378L | Q9H2Y7 | protein_coding | deleterious(0.01) | benign(0.197) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.4349G>A | p.Ser1450Asn | p.S1450N | Q9H2Y7 | protein_coding | deleterious(0.03) | probably_damaging(0.963) | TCGA-D1-A1NY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.4892G>T | p.Gly1631Val | p.G1631V | Q9H2Y7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | | c.4400C>T | p.Thr1467Met | p.T1467M | Q9H2Y7 | protein_coding | deleterious(0.03) | possibly_damaging(0.642) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | rs189641155 | c.4406N>A | p.Arg1469His | p.R1469H | Q9H2Y7 | protein_coding | tolerated(0.08) | benign(0.095) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.3644N>C | p.Val1215Ala | p.V1215A | Q9H2Y7 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.3122N>G | p.Ile1041Ser | p.I1041S | Q9H2Y7 | protein_coding | deleterious(0) | possibly_damaging(0.844) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | | c.2898N>T | p.Glu966Asp | p.E966D | Q9H2Y7 | protein_coding | deleterious(0.02) | benign(0.359) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.2628N>A | p.Phe876Leu | p.F876L | Q9H2Y7 | protein_coding | tolerated(0.46) | benign(0.006) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF106 | SNV | Missense_Mutation | novel | c.41N>G | p.Tyr14Cys | p.Y14C | | protein_coding | tolerated(0.05) | benign(0.105) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |